Annovis Bio’s Lead Candidate ANVS401 Improves Cognitive and Functional Outcomes in Stroke Mice Study

Berwyn, Pennsylvania–(Newsfile Corp. – February 2, 2021) – Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, today announced study data showing that a combination treatment using the Company’s lead candidate ANVS401 and pifithrin-α (PFT-α) after stroke improved mice locomotor activity and cognitive function more so than treatment with just one or the other agent.

The published study, “Sequential combined Treatment of Pifithrin-α and Posiphen Enhances Neurogenesis and Functional Recovery After Stroke,” was conducted by Yu “Agnes” Luo, MD, Associate Professor, Department of Neurological Surgery, School of Medicine at Case Western Reserve University in Cleveland, Ohio.

The study challenged mice with MCAo-induced stroke (middle carotid artery occlusion induced stoke) and after four weeks, the number of surviving neurons was quantified and the locomotor function, behavior, and cognition of the mice were evaluated.

While both treatments yielded improvements in locomotor and cognitive function, the combined ANVS401/PFT-α treatment proved able to enhance stroke-induced endogenous neurogenesis and improve the functional recovery in stroke animals. The combined treatment also significantly improved cognitive function more than the single treatment with PFT-α alone.

“This study adds another animal model of neurodegenerative disorders to our existing panel of animal models,” commented Maria Maccecchini, Ph.D., CEO of Annovis Bio. “To date we have shown that ANVS401 fully recovers memory and learning in animals with Alzheimer’s disease, Down syndrome and traumatic brain injury, fully recovers function in animals with Parkinson’s disease and frontotemporal dementia, and recovers sight in rats with glaucoma. In this study we have found that our drug fully recovers cognition and function in stroke mice. Each successful study further supports our plans to move into late-stage studies of ANVS401.”

About Annovis Bio

Headquartered in Berwyn, Pennsylvania, Annovis Bio, Inc. (Annovis) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Alzheimer’s in Down Syndrome (AD-DS). We believe that we are the only company developing a drug for AD, PD and AD-DS that inhibits more than one neurotoxic protein and, thereby, improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies. We expect our treatment to improve memory loss and dementia associated with AD and AD-DS, as well as body and brain function in PD. We have two ongoing Phase 2a studies: one in AD patients and one in both AD and PD patients. For more information on Annovis, please visit the company’s website: www.annovisbio.com.

Forward-Looking Statements

Statements in this press release contain “forward-looking statements” that are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “expect,” “believe,” “will,” “may,” “should,” “estimate,” “project,” “outlook,” “forecast” or other similar words, and include, without limitation, statements regarding the timing, effectiveness and anticipated results of ANVS401 clinical trials. Forward-looking statements are based on Annovis Bio, Inc.’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate, including that clinical trials may be delayed. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the Annual Report on Form 10-K for the year ended December 31, 2019 filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Annovis Bio, Inc. undertakes no duty to update such information except as required under applicable law.

Investor Relations:

Dave Gentry, CEO
RedChip Companies Inc.
407-491-4498
[email protected]

SOURCE: Annovis Bio, Inc.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/73425